News
3d
GlobalData on MSNSELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AMLThe therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...
3d
Zacks.com on MSNHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
8d
Zacks.com on MSNABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing ...
Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.
Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...
AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena. Top-line results from the CLL14 ...
13d
MedPage Today on MSNTime-Limited or Indefinite Therapy in CLLTime-limited (or fixed-duration) therapy offers a treatment-free interval, potentially leading to improved quality of life and reduced long-term toxicities. However, it may be less effective for ...
Results from the MURANO trial showed a combination of Venclexta (venetoclax) and Roche’s Rituxan (rituximab) reduced risk of disease progression or death by 83% compared with standard care in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results